Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PHENYTOIN vs BANZEL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phenytoin is a hydantoin anticonvulsant that stabilizes neuronal membranes and decreases seizure activity by increasing efflux or decreasing influx of sodium ions across cell membranes in the motor cortex during generation of nerve impulses. It use-dependently blocks voltage-gated sodium channels, prolonging their inactivation phase and reducing high-frequency repetitive firing of action potentials.
BANZEL (rufinamide) is a triazole derivative that modulates the activity of voltage-gated sodium channels. It prolongs the inactive state of sodium channels, thereby stabilizing neuronal membranes and inhibiting the repetitive firing of action potentials.
Generalized tonic-clonic seizures (grand mal epilepsy),Complex partial seizures (psychomotor/temporal lobe seizures),Prevention and treatment of seizures occurring during or following neurosurgery,Status epilepticus (intravenous formulation)
Adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) in patients 1 year of age and older (FDA-approved),Off-label: Adjunctive therapy for partial-onset seizures, generalized tonic-clonic seizures, and other refractory epilepsies
Oral: 300-400 mg/day in 3-4 divided doses; IV: 15-20 mg/kg loading dose, then 300 mg/day maintenance.
400 mg orally twice daily, titrated by 400 mg increments every 2 weeks to a maximum of 1600 mg twice daily.
Average terminal half-life 22 hours (range 7–42 hours) in adults; dose-dependent due to saturation of metabolism at therapeutic concentrations (10–20 mg/L). Half-life increases with higher doses.
Terminal elimination half-life is approximately 6-10 hours in adults; in pediatric patients, it is shorter (~3-6 hours). Steady-state is reached within 1-2 days.
Phenytoin is extensively metabolized in the liver primarily by the cytochrome P450 enzyme CYP2C9, with minor contributions from CYP2C19. The major metabolite is the glucuronide conjugate of 5-(4-hydroxyphenyl)-5-phenylhydantoin (HPPH). Phenytoin exhibits dose-dependent, saturable (Michaelis-Menten) pharmacokinetics.
Primarily hydrolyzed by carboxylesterases in the liver to inactive metabolites (CGP 47292). Minor metabolism via CYP450 enzymes (CYP2E1, CYP3A4, CYP1A2, CYP2B6, CYP2C9, CYP2C19) but not significantly.
Primarily hepatic metabolism (>95%); less than 5% excreted unchanged in urine. Renal excretion of metabolites (glucuronides) accounts for ~80% of elimination; biliary/fecal excretion of metabolites ~20%.
Primarily renal: approximately 66% of the dose excreted in urine (30% as unchanged rufinamide, 70% as inactive metabolites). Fecal excretion: ~4%. No significant biliary excretion.
90–95% bound, primarily to albumin; binding is saturable and decreases in hypoalbuminemia, uremia, or with other highly bound drugs.
Approximately 34% bound to plasma proteins, primarily albumin.
0.6–0.8 L/kg; indicates extensive tissue distribution; crosses blood-brain barrier; Vd increases in neonates and decreases in renal failure.
Apparent volume of distribution is approximately 0.7-1.0 L/kg, indicating distribution primarily into total body water.
Oral: 90–100% (phenytoin sodium extended-release); IM: low and erratic (not recommended) due to precipitation and slow absorption.
Absolute oral bioavailability is approximately 85% (high). Food increases Cmax and AUC by about 30-40%, but this is not considered clinically significant for dosing.
No specific GFR-based adjustment required; use with caution in severe renal impairment (GFR < 10 m L/min) due to protein binding changes.
Cr Cl < 30 m L/min: not recommended. Cr Cl 30-50 m L/min: maximum dose 400 mg twice daily. Cr Cl > 50 m L/min: no adjustment.
Child-Pugh A: No adjustment; Child-Pugh B: Reduce dose by 25-50%; Child-Pugh C: Reduce dose by 50-75%.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: start 200 mg twice daily, maximum 400 mg twice daily. Child-Pugh Class C: not recommended.
Loading dose: 15-20 mg/kg IV/PO; Maintenance: 5-10 mg/kg/day PO in 2-3 divided doses.
Age ≥4 years: based on body weight. Starting dose: 10 mg/kg/day divided twice daily, titrate weekly by increments of 10 mg/kg/day to target maintenance 40 mg/kg/day (max 3200 mg/day). Max single dose: 1600 mg twice daily.
Start at low end of dosing range (e.g., 3 mg/kg/day); monitor for toxicity; consider reduced protein binding and slower metabolism.
No specific dose adjustment, but consider age-related renal impairment; monitor Cr Cl.
Intravenous administration of phenytoin is associated with serious cardiovascular adverse reactions including severe hypotension and cardiac arrhythmias (e.g., bradycardia, heart block, ventricular fibrillation). These reactions can occur more frequently in patients with advanced age, known cardiac disease, or those receiving other medications that affect the cardiovascular system. Continuous monitoring of ECG and vital signs is required during IV administration, and the rate of infusion should not exceed 50 mg/min in adults.
None
Cardiovascular risk during IV administration (see black box warning),Hypersensitivity reactions: Angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS),Hepatic injury: Acute hepatotoxicity, including elevated liver enzymes and hepatitis,Hematologic effects: Agranulocytosis, thrombocytopenia, leukopenia, pancytopenia,Central nervous system effects: Nystagmus, ataxia, slurred speech, mental confusion, dizziness, drowsiness,Hyperglycemia: May elevate blood glucose levels,Osteomalacia and hypocalcemia due to altered vitamin D metabolism,Teratogenicity: Fetal hydantoin syndrome (craniofacial abnormalities, growth deficiency, intellectual disability),Birth defects: Increased risk of cardiovascular malformations and neural tube defects,Carcinogenicity: Long-term use associated with increased risk of malignancies (lymphoma, hepatocellular carcinoma)
May shorten QT interval; use caution with other drugs that shorten QT interval. Increased risk of suicidal thoughts/behavior. Monitor for hypersensitivity reactions (including DRESS). Central nervous system depression (dizziness, somnolence, ataxia). May decrease efficacy of hormonal contraceptives. Withdrawal seizures if abruptly discontinued. Dose adjustment needed in severe hepatic impairment.
Hypersensitivity to phenytoin, other hydantoins, or any component of the formulation,Sinus bradycardia, sinoatrial block, second- or third-degree AV block, Adams-Stokes syndrome,Concurrent use with delavirdine (due to decreased delavirdine concentrations),History of prior acute hepatotoxicity attributable to phenytoin,Porphyria (may precipitate acute attacks)
Familial short QT syndrome (due to QT interval shortening). Hypersensitivity to rufinamide or any of its components.
Enteral tube feedings can decrease phenytoin absorption; hold feeds 1-2 hours before and after administration. High-fat meals may increase absorption consistency. Folic acid supplementation may lower phenytoin levels. Calcium supplements and antacids can impair absorption; separate by 2-3 hours.
BANZEL should be taken with food to increase bioavailability (Cmax increases by approximately 40% and AUC by 50% compared to fasting). Avoid grapefruit juice as it may alter drug metabolism. No other food interactions are documented.
Phenytoin is associated with fetal hydantoin syndrome, including craniofacial dysmorphisms, cardiac defects, neural tube defects, and cognitive impairment. Risk is highest during first trimester (organogenesis). Second and third trimester exposure may cause impaired fetal growth, microcephaly, and neurodevelopmental delay. Risk of major malformations is dose-dependent and increases with polytherapy.
First trimester: Increased risk of major congenital malformations, including neural tube defects, craniofacial defects, and cardiac anomalies. Second and third trimesters: Risk of intrauterine growth restriction, neurodevelopmental delay, and hemorrhagic disease of the newborn due to vitamin K deficiency.
Phenytoin is excreted into breast milk with estimated infant dose of 2-10% of maternal weight-adjusted dose; M/P ratio approximately 0.18-0.45. Generally considered compatible with breastfeeding; monitor infant for drowsiness, poor feeding, and rash. Avoid if maternal dose >400 mg/day or signs of infant toxicity.
Rufinamide is excreted in human milk. The milk-to-plasma ratio is approximately 0.3. Breastfeeding is not recommended due to potential adverse effects in the infant, including somnolence, poor feeding, and weight loss.
Pregnancy decreases phenytoin concentrations due to increased clearance (hepatic induction, increased Vd, decreased albumin). Dose adjustments are frequently required: increase total daily dose by 30-50% on average, guided by free phenytoin concentrations (target 1-2 mcg/m L). Monitor serum levels every 2-4 weeks, especially in third trimester. Postpartum, dose should be reduced to prepregnancy levels over 1-2 weeks to avoid toxicity.
Pregnancy may reduce serum concentrations due to increased clearance and volume of distribution. Monitor trough levels and adjust dose to maintain therapeutic efficacy. Postpartum, monitor for toxicity as levels may rise.
Phenytoin exhibits zero-order kinetics at therapeutic levels; small dose increases can cause toxicity. Monitor free phenytoin levels in hypoalbuminemia or uremia. Fosphenytoin is a prodrug used for IV loading with fewer infusion-site reactions. Caution in CYP2C9 poor metabolizers; consider genetic testing. May cause folate deficiency, peripheral neuropathy, and osteomalacia with long-term use. Co-administration with valproate displaces phenytoin from protein binding, increasing free fraction.
BANZEL (rufinamide) is an antiepileptic drug indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients ≥1 year. Titrate slowly over 2-3 weeks to reduce risk of adverse effects. Monitor for shortened QT interval; contraindicated in familial short QT syndrome. Dose adjustments needed in severe hepatic impairment. May decrease efficacy of oral contraceptives containing ethinyl estradiol. Administer with food to enhance absorption.
Take exactly as prescribed; do not skip doses or change brands without consulting your doctor.,Do not stop taking suddenly as this may cause withdrawal seizures.,Avoid alcohol as it can affect drug levels and increase side effects.,Report any rash, fever, swollen glands, or mouth sores immediately (risk of Stevens-Johnson syndrome).,Use reliable contraception if sexually active; phenytoin reduces effectiveness of hormonal contraceptives.,Maintain good dental hygiene and see dentist regularly; may cause gum overgrowth.,Take with food if stomach upset occurs, but avoid high-fat meals if consistent timing is needed.,May cause dizziness, drowsiness, or blurred vision; avoid driving until you know how it affects you.
Take BANZEL exactly as prescribed with food to improve absorption.,Do not stop taking BANZEL suddenly; taper under medical supervision to avoid withdrawal seizures.,Inform your doctor if you have a heart condition, especially short QT syndrome.,Use effective contraception if applicable; BANZEL may reduce efficacy of oral contraceptives.,Monitor for dizziness, drowsiness, or coordination problems; avoid driving until you know how BANZEL affects you.,Report any unusual tiredness, fatigue, or signs of liver injury (yellowing skin/eyes, dark urine) immediately.
"Coadministration of phenytoin and dexbrompheniramine may increase the risk of central nervous system (CNS) depression, leading to excessive sedation, dizziness, and impaired psychomotor function. Phenytoin, a sodium channel blocker used for seizure control, and dexbrompheniramine, a first-generation antihistamine with strong anticholinergic and sedative properties, synergistically depress CNS activity. This interaction can result in additive sedation, potentially compromising patient safety, especially in activities requiring alertness."
"Phenytoin is a potent inducer of cytochrome P450 (CYP) 3A4 and other drug-metabolizing enzymes. Dasatinib is primarily metabolized by CYP3A4. Coadministration with phenytoin significantly reduces dasatinib plasma concentrations, potentially leading to subtherapeutic levels, reduced efficacy, and increased risk of disease progression in chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia."
"Phenytoin, a known inducer of CYP450 enzymes (particularly CYP3A4 and CYP2C9), increases the hepatic metabolism of ambroxol, a mucolytic agent primarily metabolized via CYP3A4. This induction reduces ambroxol plasma concentrations, potentially diminishing its therapeutic efficacy in clearing respiratory secretions. Clinically, patients may experience reduced mucolytic effects, leading to inadequate clearance of bronchial secretions and worsening of underlying respiratory conditions."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PHENYTOIN vs BANZEL, answered by our medical review team.
PHENYTOIN is a Anticonvulsant that works by Phenytoin is a hydantoin anticonvulsant that stabilizes neuronal membranes and decreases seizure activity by increasing efflux or decreasing influx of sodium ions across cell membranes in the motor cortex during generation of nerve impulses. It use-dependently blocks voltage-gated sodium channels, prolonging their inactivation phase and reducing high-frequency repetitive firing of action potentials.. BANZEL is a Anticonvulsant that works by BANZEL (rufinamide) is a triazole derivative that modulates the activity of voltage-gated sodium channels. It prolongs the inactive state of sodium channels, thereby stabilizing neuronal membranes and inhibiting the repetitive firing of action potentials.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PHENYTOIN and BANZEL depend on the specific clinical indication. These are both Anticonvulsant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PHENYTOIN is: Oral: 300-400 mg/day in 3-4 divided doses; IV: 15-20 mg/kg loading dose, then 300 mg/day maintenance.. The standard adult dose of BANZEL is: 400 mg orally twice daily, titrated by 400 mg increments every 2 weeks to a maximum of 1600 mg twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PHENYTOIN and BANZEL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PHENYTOIN is classified as Category D/X. Phenytoin is associated with fetal hydantoin syndrome, including craniofacial dysmorphisms, cardiac defects, neural tube defects, and cognitive impairment. Risk is highest during f. BANZEL is classified as Category C. First trimester: Increased risk of major congenital malformations, including neural tube defects, craniofacial defects, and cardiac anomalies. Second and third trimesters: Risk of . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.